Essential Partners LLC Has $197,000 Stake in United Therapeutics Corporation $UTHR

Essential Partners LLC trimmed its position in United Therapeutics Corporation (NASDAQ:UTHR) by 78.9% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 333 shares of the biotechnology company’s stock after selling 1,247 shares during the period. Essential Partners LLC’s holdings in United Therapeutics were worth $197,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Torren Management LLC bought a new position in shares of United Therapeutics during the fourth quarter worth about $26,000. Activest Wealth Management lifted its stake in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares in the last quarter. WealthCollab LLC lifted its stake in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. boosted its position in United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares during the last quarter. Finally, Entrust Financial LLC acquired a new position in United Therapeutics during the 4th quarter worth approximately $31,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at United Therapeutics

In related news, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $578.58, for a total transaction of $5,785,800.00. Following the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $10,921,276.08. The trade was a 34.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 502,833 shares of company stock valued at $279,377,162 over the last three months. 8.60% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on UTHR shares. Raymond James Financial initiated coverage on shares of United Therapeutics in a research note on Friday, April 10th. They set an “outperform” rating and a $700.00 price target for the company. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. JPMorgan Chase & Co. raised their target price on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Finally, Royal Bank Of Canada lifted their price target on shares of United Therapeutics from $701.00 to $704.00 and gave the company an “outperform” rating in a research note on Tuesday, July 7th. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $648.33.

United Therapeutics Stock Down 1.5%

UTHR stock opened at $517.71 on Friday. The company has a market cap of $21.98 billion, a price-to-earnings ratio of 19.11, a P/E/G ratio of 1.76 and a beta of 0.58. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35. The business has a 50 day moving average price of $543.63 and a two-hundred day moving average price of $532.44.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The company’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $6.63 EPS. On average, equities research analysts anticipate that United Therapeutics Corporation will post 26.65 EPS for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.